Richmond Pharmacology is pleased to announce our attendance at ESC Congress 2025, the European Society of Cardiology’s flagship event, held in Madrid from 29thAugust– 1st September.

 

Representing Richmond Pharmacology at ESC Congress:
Dr Jörg Täubel, Chief Executive Officer

 

DrTäubel looks forward to connecting with clinicians, researchers, and industryleaders, sharing Richmond’s expertise in:
• Early-phase cardiovascular and cardiometabolic trials
• Novel endpoints and digital health integration
• Risk-stratified study design and cardiac safety
• Accelerated CV drug development pathways
• Patient-focused recruitment and retention

 

If you’re attending ESC 2025 and seeking an expert partner for cardiovascular clinical trials, we welcome meeting requests at: info@richmondpharmacology.com

Learn more: ESC2025 | ESC 2025 Registration | ESC Annual Congress 2025

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event